HRP20210455T1 - Anti-orai1 antitijelo - Google Patents
Anti-orai1 antitijelo Download PDFInfo
- Publication number
- HRP20210455T1 HRP20210455T1 HRP20210455TT HRP20210455T HRP20210455T1 HR P20210455 T1 HRP20210455 T1 HR P20210455T1 HR P20210455T T HRP20210455T T HR P20210455TT HR P20210455 T HRP20210455 T HR P20210455T HR P20210455 T1 HRP20210455 T1 HR P20210455T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- seq
- positions
- diseases
- acid residues
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 27
- 125000000539 amino acid group Chemical group 0.000 claims 26
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 6
- 230000002757 inflammatory effect Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 238000006243 chemical reaction Methods 0.000 claims 5
- 239000003146 anticoagulant agent Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 230000000702 anti-platelet effect Effects 0.000 claims 2
- 230000002785 anti-thrombosis Effects 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010002216 Anaphylactoid reaction Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000017452 Epidermal disease Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 208000007811 Latex Hypersensitivity Diseases 0.000 claims 1
- 206010024380 Leukoderma Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039251 Rubber sensitivity Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000004169 Stormorken syndrome Diseases 0.000 claims 1
- 208000034593 Stormorken-Sjaastad-Langslet syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000032978 Structural Congenital Myopathies Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 230000020411 cell activation Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 208000030172 endocrine system disease Diseases 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000023589 ischemic disease Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000005391 latex allergy Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000000516 mast-cell leukemia Diseases 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000002346 musculoskeletal system Anatomy 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 206010040560 shock Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 206010044325 trachoma Diseases 0.000 claims 1
- 201000010156 tubular aggregate myopathy Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Claims (13)
1. Antitijelo ili antigen-vezujući fragment antitijela koji se specifično vezuje za aminokiselinsku sekvencu predstavljenu pomoću SEQ ID NO: 2, pri čemu antitijelo sadrži:
a) sekvencu varijabilnog regiona teškog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 20 do 136 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 62 i sekvencu varijabilnog regiona lakog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 21 do 126 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 56;
b) sekvencu varijabilnog regiona teškog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 20 do 136 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 62 i sekvencu varijabilnog regiona lakog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 21 do 126 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 58;
c) sekvencu varijabilnog regiona teškog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 20 do 136 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 62 i sekvencu varijabilnog regiona lakog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 21 do 126 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 60;
d) sekvencu varijabilnog regiona teškog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 20 do 136 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 64 i sekvencu varijabilnog regiona lakog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 21 do 126 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 56;
e) sekvencu varijabilnog regiona teškog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 20 do 136 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 66 i sekvencu varijabilnog regiona lakog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 21 do 126 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 56; ili
f) sekvencu varijabilnog regiona teškog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 20 do 136 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 43 i sekvencu varijabilnog regiona lakog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 21 do 126 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 56.
2. Antitijelo ili antigen-vezujući fragment antitijela prema patentnom zahtjevu 1, pri čemu se antitijelo sastoji od:
a) sekvence teškog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 20 do 465 ili 20 do 466 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 62 i sekvence lakog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 21 do 234 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 56;
b) sekvence teškog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 20 do 465 ili 20 do 466 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 70 i sekvence lakog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 21 do 234 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 56;
c) sekvence teškog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 20 do 465 ili 20 do 466 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 62 i sekvence lakog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 21 do 234 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 58;
d) sekvence teškog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 20 do 465 ili 20 do 466 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 62 i sekvence lakog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 21 do 234 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 60;
e) sekvence teškog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 20 do 465 ili 20 do 466 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 64 i sekvence lakog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 21 do 234 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 56;
f) sekvence teškog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 20 do 465 ii 20 do 466 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 66 i sekvence lakog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 21 do 234 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 56; ili
g) sekvence teškog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 20 do 465 ili 20 do 466 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 43 i sekvence lakog lanca koja se sastoji od aminokiselinskih ostataka sa položaja 21 do 235 u aminokiselinskoj sekvenci predstavljenoj pomoću SEQ ID NO: 56.
3. Antigen-vezujući fragment antitijela prema patentnom zahtjevu 1, pri čemu je antigen-vezujući fragment odabran od grupe koja se sastoji od Fab, F(ab')2, Fab' i Fv.
4. Antitijelo prema patentnom zahtjevu 1, pri čemu je antitijelo scFv.
5. Farmaceutska kompozicija koja sadrži najmanje bilo koje antitijelo ili antigen-vezujući fragment antitijela prema patentnim zahtjevima 1 do 4.
6. Farmaceutska kompozicija prema patentnom zahtjevu 5, pri čemu je farmaceutska kompozicija terapijski i/ili profilaktički agens za odbacivanja transplanta, bolesti povezane sa imunološkim sustavom, alergijske bolesti, inflamatorne bolesti, ili karcinome ili antitrombocitni ili antitrombotički aktivator.
7. Farmaceutska kompozicija prema patentnom zahtjevu 6, pri čemu su odbacivanja transplanta reakcije odbacivanja i reakcije domaćin protiv kalema na transplantaciju organa ili tkiva kao što su srce, bubreg, jetra, koštana srž, ili koža, i bolest kalem protiv domaćina uzrokovana transplantacijom hematopoetskih stanica (kao što su koštana srž, periferna krv ili krv iz pupčane vrpce).
8. Farmaceutska kompozicija prema patentnom zahtjevu 6, pri čemu su
bolesti u vezi sa imunološkim sustavom bolesti vezivnog tkiva ili mišićno-koštanog sustava (kao što je reumatoidni artritis, ankilozirajući spondilitis, sustavni lupus eritematozus, skleroderma, polimiozitis ili dermatomiozitis), hematološke bolesti (kao što je aplastična anemija ili idiopatska trombocitopenijska purpura), gastrointestinalne bolesti (kao što je Kronova bolest ili ulcerativni kolitis), neurološke bolesti (kao što je multipla skleroza ili mijastenija gravis), oftamološke bolesti (kao što je uveitis), vaskularne bolesti (kao što je Behçetova bolest ili Wegenerova granulomatoza), epidermalne bolesti (kao što je psorijaza, pemphigus ili leukoderma) i endokrine bolesti (kao što je dijabetes melitus tip 1, autoimuni tiroiditis, Gravesova bolest ili Hashimotova bolest),
alergijske bolesti su atopijski dermatitis, astma, anafilaksa, anafilaktoidna reakcija, alergija na hranu, rinitis, otitis media, reakcija na lijek, reakcija na ubod insekta, reakcija na biljke, alergija na lateks, konjuktivitis i urtikarija, i
inflamatorne bolesti su inflamatorne bubrežne bolesti (kao što je glomerulonefritis ili nefroza), inflamatorne plućne bolesti (kao što je kronična opstruktivna bolest pluća, cistična fibroza ili intersticijalna pneumonija), inflamatorne bolesti crijeva (kao što je ulcerativni kolitis ili ileitis), inflamatorne bolesti jetre (kao što je autoimunski hepatitis ili virusni hepatitis), inflamatorne bolesti srca (kao što je miokarditis, ishemijska bolest srca ili ateroskleroza), inflamatorne bolesti kože (kao što je kontaktni dermatitis ili ekcem), inflamatorne bolesti oka (kao što je trahom ili endoftalmitis), inflamatorne bolesti centralnog živčanog sustava (kao što je meningitis, encefalomijelitis ili autoimuni encefalitis), inflamatorne bolesti zgloba (kao što je artritis ili osteoartritis), i sustavne upale (kao što je sepsa, krvarenje, preosjetljivost ili simptomi šoka koji se pripisuju kemoterapiji karcinoma).
9. Farmaceutska kompozicija prema patentnom zahtjevu 6, pri čemu su karcinomi, rak dojke, rak pluća, rak kože i leukemija, i slučajevi u kojima je antitrombocitna ili antitrombotička aktivnost korisna za liječenje i/ili prevenciju su infarkt miokarda, moždani udar, ishemijske bolesti srca, i tromboze, a slučajevi u kojima je inhibicija aktivacije stanice koja eksprimira Orail korisna za liječenje i/ili prevenciju su leukemija mastocita, mastocitoza, bazofilna leukemija, endometrioza, Stormorken sindrom, tubularna agregatna miopatija, reumatoidni artritis, ankilozirajući spondilitis i atopijski dermatitis.
10. Polinukleotid koji kodira antitijelo ili antigen-vezujući fragment antitijela prema bilo kojem od patentnih zahtjeva 1 do 4.
11. Vektor koji sadrži polinuklotid prema patentnom zahtjevu 10.
12. Transformirana stanica domaćina koja sadrži polinuklotid prema patentnom zahtjevu 10 ili vektor prema patentnom zahtjevu 11.
13. Postupak za proizvodnju antitijela ili antigen-vezujućeg fragmenta antitijela prema bilo kojem od patentnih zahtjeva 1 do 4, koji obuhvaća korak kultiviranja stanice domaćina prema patentnom zahtjevu 12 i pročišćavanje antitijela iz proizvoda kulture.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014161449 | 2014-08-07 | ||
PCT/JP2015/072305 WO2016021674A1 (ja) | 2014-08-07 | 2015-08-06 | 抗Orai1抗体 |
EP15830516.9A EP3178931B1 (en) | 2014-08-07 | 2015-08-06 | Anti-orai1 antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20210455T1 true HRP20210455T1 (hr) | 2021-06-25 |
Family
ID=55263931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20210455TT HRP20210455T1 (hr) | 2014-08-07 | 2021-03-18 | Anti-orai1 antitijelo |
Country Status (28)
Country | Link |
---|---|
US (2) | US10351624B2 (hr) |
EP (1) | EP3178931B1 (hr) |
JP (3) | JP6125110B2 (hr) |
KR (1) | KR102500401B1 (hr) |
CN (1) | CN106795512B (hr) |
AU (1) | AU2015300037C1 (hr) |
BR (1) | BR112017002333A2 (hr) |
CA (1) | CA2957502C (hr) |
CO (1) | CO2017001626A2 (hr) |
CY (1) | CY1124021T1 (hr) |
DK (1) | DK3178931T3 (hr) |
ES (1) | ES2861313T3 (hr) |
HR (1) | HRP20210455T1 (hr) |
HU (1) | HUE054148T2 (hr) |
IL (1) | IL250475B (hr) |
LT (1) | LT3178931T (hr) |
MX (1) | MX2017001629A (hr) |
MY (2) | MY183230A (hr) |
NZ (1) | NZ729075A (hr) |
PH (1) | PH12017500217B1 (hr) |
PL (1) | PL3178931T3 (hr) |
PT (1) | PT3178931T (hr) |
RS (1) | RS61588B1 (hr) |
RU (1) | RU2724742C2 (hr) |
SG (2) | SG10201900862WA (hr) |
SI (1) | SI3178931T1 (hr) |
TW (1) | TWI671316B (hr) |
WO (1) | WO2016021674A1 (hr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201990296A1 (ru) | 2016-08-05 | 2019-08-30 | Аллакос, Инк. | Антитела против siglec-7 для лечения рака |
WO2019140273A1 (en) * | 2018-01-11 | 2019-07-18 | Allakos, Inc. | Anti-siglec-7 antibodies having reduced effector function |
CN108562748A (zh) * | 2018-03-28 | 2018-09-21 | 深圳承启生物科技有限公司 | Orai1蛋白和/或STIM1蛋白作为脑卒中生物标志物的用途 |
DE102019106711A1 (de) | 2019-03-15 | 2020-09-17 | Grob-Werke Gmbh & Co. Kg | Verfahren und Vorrichtung zum mehrlagigen Einfügen einer Spulenmatte in ein Bauteil einer elektrischen Maschine |
CN111273015B (zh) * | 2020-04-13 | 2023-04-11 | 北京维德维康生物技术有限公司 | 一种检测短裸甲藻毒素的酶联免疫试剂盒及其制备和应用 |
WO2023049867A1 (en) * | 2021-09-24 | 2023-03-30 | Seeker Biologics, Inc. | Orai1 multispecific antibodies and methods of use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2368912B1 (en) | 2006-01-05 | 2017-05-03 | Children's Medical Center Corporation | Regulators of NFAT |
AU2007238225A1 (en) * | 2006-04-10 | 2007-10-25 | Beth Israel Deaconess Medical Center | CRAC modulators and use of same for drug discovery |
EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
GB0801888D0 (en) * | 2008-02-01 | 2008-03-12 | Isis Innovation | Treatment of mast cell related disorders |
MX2012005864A (es) | 2009-11-20 | 2012-08-31 | Amgen Inc | Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas. |
WO2013091903A1 (en) * | 2011-12-22 | 2013-06-27 | Novo Nordisk A/S | Anti-crac channel antibodies |
-
2015
- 2015-08-06 US US15/502,088 patent/US10351624B2/en active Active
- 2015-08-06 CA CA2957502A patent/CA2957502C/en active Active
- 2015-08-06 DK DK15830516.9T patent/DK3178931T3/da active
- 2015-08-06 EP EP15830516.9A patent/EP3178931B1/en active Active
- 2015-08-06 HU HUE15830516A patent/HUE054148T2/hu unknown
- 2015-08-06 KR KR1020177003295A patent/KR102500401B1/ko active IP Right Grant
- 2015-08-06 SI SI201531538T patent/SI3178931T1/sl unknown
- 2015-08-06 NZ NZ729075A patent/NZ729075A/en unknown
- 2015-08-06 SG SG10201900862WA patent/SG10201900862WA/en unknown
- 2015-08-06 BR BR112017002333-4A patent/BR112017002333A2/pt active Search and Examination
- 2015-08-06 CN CN201580054267.1A patent/CN106795512B/zh active Active
- 2015-08-06 TW TW104125587A patent/TWI671316B/zh active
- 2015-08-06 WO PCT/JP2015/072305 patent/WO2016021674A1/ja active Application Filing
- 2015-08-06 MY MYPI2017000191A patent/MY183230A/en unknown
- 2015-08-06 SG SG11201700922YA patent/SG11201700922YA/en unknown
- 2015-08-06 JP JP2016540730A patent/JP6125110B2/ja active Active
- 2015-08-06 ES ES15830516T patent/ES2861313T3/es active Active
- 2015-08-06 RS RS20210326A patent/RS61588B1/sr unknown
- 2015-08-06 MY MYPI2021000506A patent/MY196283A/en unknown
- 2015-08-06 PT PT158305169T patent/PT3178931T/pt unknown
- 2015-08-06 RU RU2017107197A patent/RU2724742C2/ru active
- 2015-08-06 MX MX2017001629A patent/MX2017001629A/es unknown
- 2015-08-06 PL PL15830516T patent/PL3178931T3/pl unknown
- 2015-08-06 AU AU2015300037A patent/AU2015300037C1/en active Active
- 2015-08-06 LT LTEP15830516.9T patent/LT3178931T/lt unknown
-
2017
- 2017-02-02 JP JP2017017757A patent/JP2017137310A/ja active Pending
- 2017-02-03 PH PH12017500217A patent/PH12017500217B1/en unknown
- 2017-02-06 IL IL250475A patent/IL250475B/en unknown
- 2017-02-20 CO CONC2017/0001626A patent/CO2017001626A2/es unknown
- 2017-03-16 JP JP2017051054A patent/JP6599916B2/ja active Active
-
2019
- 2019-07-02 US US16/460,632 patent/US10851162B2/en active Active
-
2021
- 2021-03-18 HR HRP20210455TT patent/HRP20210455T1/hr unknown
- 2021-04-02 CY CY20211100285T patent/CY1124021T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210455T1 (hr) | Anti-orai1 antitijelo | |
AR084845A1 (es) | Moleculas de anticuerpos que se unen a il-17a e il-17f | |
AR083785A1 (es) | Anticuerpos humanos contra el ligando 1a de tipo tnf (factor de necrosis tumoral) humano (tl1a) | |
IN2015DN02008A (hr) | ||
HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
HRP20171045T1 (hr) | Protutijela anti-vla-4 | |
PH12017500966A1 (en) | Pharmaceutical products and stable liquid compositions of il-17 antibodies | |
CO7010835A2 (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios | |
EA201591462A1 (ru) | Антитела против il-17a и их применение для лечения аутоиммунных и воспалительных нарушений | |
NZ737355A (en) | Compounds targeting proteins, compositions, methods, and uses thereof | |
WO2013169806A3 (en) | Biogenic activated carbon and methods of making and using same | |
WO2016164669A3 (en) | Antibody therapeutics that bind cd38 | |
JP2016515524A5 (hr) | ||
TN2015000348A1 (en) | Antibodies that bind il-23 | |
MD3350223T2 (ro) | Anticorpi care se leagă specific la TL1A | |
JP2015527978A5 (hr) | ||
RU2019126888A (ru) | Антитело к человеческому аннексину а1 | |
JP2016520595A5 (hr) | ||
EA201300418A1 (ru) | Антитела к человеческому tweak и варианты их применения | |
JP2015520182A5 (hr) | ||
MX2018011865A (es) | Composiciones de inmunoglobulina intravenosa recombinante (rivig) y metodos para su produccion y uso. | |
EA202090401A1 (ru) | Анти-tim-3 антитела и их применение | |
CL2017000774A1 (es) | Método para producir gránulos de sulfato de potasio y el granulado de potasio derivado del mismo, así como también el uso del mismo. | |
NZ609572A (en) | Oxazoline and isoxazoline derivatives as crac modulators | |
HRP20170745T1 (hr) | Kristalni oblik natrijeve soli 4-tert-butil-n-[4-kloro-2-(1-oksipiridin-4-karbonil)-fenil]-benzensulfonamida |